Drugs / AT-101
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00934076 | Feb 2010 → Jan 2011 | non-small cell lung carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05338931 | Mar 2022 → Mar 2030 expected | B-cell non-Hodgkin lymphoma | AbClon | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00561197 | Aug 2007 → Sep 2010 | gastroesophageal cancer | Ascenta Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT00397293 | Nov 2006 → Dec 2008 | small cell lung carcinoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00286793 | Feb 2006 → Nov 2009 | prostate cancer | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00286806 | Dec 2005 → Jun 2007 | hormone-resistant prostate carcinoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT01633541 | Mar 2012 → Nov 2021 | larynx cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01285635 | Jun 2010 → Dec 2012 | head and neck squamous cell carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00988169 | Sep 2009 → May 2010 | lung cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00666666 | Jul 2009 → May 2011 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00571675 | Oct 2007 → Sep 2010 | hormone-resistant prostate carcinoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00544960 | Sep 2007 → Nov 2008 | non-small cell lung carcinoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00440388 | Oct 2006 → Nov 2008 | follicular lymphoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00286780 | Jan 2006 → Nov 2007 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascenta Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00275431 | Nov 2005 → Dec 2008 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Ascenta Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT-101 | “Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer” NCT00397293 ↗ |
| Known as | h1218-CART19 | “We conducted a first-in-human multi-center phase I clinical trial to test AT101 (clinical-grade h1218-CART19) in patients with relapsed or refractory (r/r) NHL.” PMID 38066564 ↗ Dec 2023 |
| Action | Inhibit | “It is proposed that the effects of AT-101 on the downstream signaling pathways of the EGFR, particularly inhibition of the anti-apoptotic members Bcl-2 family of proteins, may...” NCT00934076 ↗ |
| Modality | Small molecule | “Phase I/II testing of the small molecule inhibitor, AT-101, has recently been completed” NCT01633541 ↗ |
| Route | Oral | “Oral” NCT00275431 ↗ |
| Target | BCL2 | “the novel pan-Bcl-2 inhibitor, AT-101” NCT00988169 ↗ |